Pancreatic Cancer Research

ResearcherDuke UniversityActive in the last 2 years

Daniel P. Nussbaum

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3070-6605; OpenAlex author ID A5008831926. Sources: ClinicalTrials.gov.

Their work

Papers
13 (first author 1, last author 4)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper, 1 trial · 2025: 2 papers · 2026: 5 papers · 2027: 1 trial

Papers 13

  1. Comparing traditional versus total neoadjuvant chemotherapy for patients with localized pancreatic cancer. Last author DOI 10.1016/j.hpb.2025.11.001↗
  2. Assessing PANACHE's Style and Substance for Deep Learning Prognostication in Pancreatic Cancer. Last author DOI 10.1200/cci-26-00029↗
  3. Preparing for the Inevitable: Early Comprehensive Genomic Profiling for Patients With Localized Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1200/op-25-00548↗
  4. Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer. Co-author DOI 10.1200/po-25-00115↗
  5. Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Veterans Affairs Patients. Co-author DOI 10.1245/s10434-025-18232-6↗
  6. A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. Co-author DOI 10.1007/s00262-025-04146-5↗
  7. SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multic… Co-author DOI 10.1097/sla.0000000000006966↗
  8. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-14751-2↗
  9. Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemotherapy. Last author DOI 10.1245/s10434-023-13318-5↗
  10. Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node … Co-author DOI 10.1007/s00423-020-01859-2↗
  11. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. First author DOI 10.1002/jso.24630↗
  12. Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. Co-author DOI 10.1097/sla.0000000000001924↗
  13. Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4937-x↗

Trials 2

  1. A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer Principal investigator NCT07905131↗
  2. Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer Principal investigator NCT05634720↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elishama N. Kanu · 6 shared papers, 2023–2026 · strength 1.40
  2. Peter J. Allen · 5 shared papers, 2023–2026 · strength 1.31
  3. Ethan S. Agritelley · 4 shared papers, 2025–2026 · strength 1.06
  4. Dan German Blazer · 7 shared papers, 2016–2026 · strength 1.02
  5. Michael E. Lidsky · 5 shared papers, 2017–2026 · strength 0.97
  6. John Strickler · 1 shared trial, 2027 · strength 0.95
  7. Julia Button · 3 shared papers, 2025–2026 · strength 0.72
  8. Ryne C. Ramaker · 2 shared papers, 2026 · strength 0.67
  9. Austin M. Eckhoff · 3 shared papers, 2023–2025 · strength 0.62
  10. Peter J. Allen · 2 shared papers, 2025–2026 · strength 0.53
  11. Joey Lew · 1 shared paper, 2026 · strength 0.50
  12. Sabino Zani · 2 shared papers, 2023–2025 · strength 0.39
  13. John H. Strickler · 1 shared paper, 2026 · strength 0.33
  14. Sabran J. Masoud · 1 shared paper, 2026 · strength 0.30
  15. Allison N. Martin · 1 shared paper, 2026 · strength 0.30
  16. Zahra Kabiri · 1 shared paper, 2026 · strength 0.26
  17. Sara Raji · 1 shared paper, 2026 · strength 0.26
  18. Mohamed A. Adam · 3 shared papers, 2016–2017 · strength 0.22
  19. Tao Wang · 1 shared paper, 2025 · strength 0.20
  20. Erika J. Crosby · 1 shared paper, 2025 · strength 0.20
  21. Erin M. Dickey · 1 shared paper, 2025 · strength 0.19
  22. David G. Brauer · 1 shared paper, 2025 · strength 0.19
  23. Caitlin A. Hester · 1 shared paper, 2025 · strength 0.19
  24. Brian E. Diskin · 1 shared paper, 2025 · strength 0.19
  25. Emil Lou · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.